Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus model Anti-BCMA panCARTM program showed robust and durable plasma cell depletion in preclinical models Orna expects to submit its first Clinical...
Hence then, the article about orna therapeutics presents new data supporting its in vivo car programs for autoimmune diseases and oncology at the 67th american society of hematology annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting )
Also on site :
- Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
- Reported tornado rips roofs off multiple homes in central Illinois
- John Legend Celebrates 47th Birthday With Family Slime Outing in New York